Cargando…
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
OBJECTIVES: Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus which remains latent in individuals after a varicella infection. It is expected that HZ will be more frequent in immunocompromised (IC) individuals than in immunocompetent (IC-free). This study assessed the incidence...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009512/ https://www.ncbi.nlm.nih.gov/pubmed/29880565 http://dx.doi.org/10.1136/bmjopen-2017-020528 |
_version_ | 1783333402638811136 |
---|---|
author | Yanni, Emad A. Ferreira, Germano Guennec, Morgane El Hahi, Yassine El Ghachi, Amale Haguinet, François Espie, Emmanuelle Bianco, Veronique |
author_facet | Yanni, Emad A. Ferreira, Germano Guennec, Morgane El Hahi, Yassine El Ghachi, Amale Haguinet, François Espie, Emmanuelle Bianco, Veronique |
author_sort | Yanni, Emad A. |
collection | PubMed |
description | OBJECTIVES: Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus which remains latent in individuals after a varicella infection. It is expected that HZ will be more frequent in immunocompromised (IC) individuals than in immunocompetent (IC-free). This study assessed the incidence rate (IR) of HZ in individuals with a wide set of IC conditions and in IC-free individuals. SETTING: A retrospective cohort study was conducted in England using data (January 2000 to March 2012) from the Clinical Practice Research Datalink with linkage to the Hospital Episodes Statistics. PARTICIPANTS: A cohort of 621 588 individuals with 16 selected IC conditions and a gender/age-matched cohort of IC-free individuals were identified. The IC conditions included haematopoietic stem cell transplant (HSCT), solid organ transplant, malignancies, autoimmune diseases and users of immunosuppressive medications. OUTCOMES: IR of HZ per 1000 person-years (PY) was estimated. Proportions of postherpetic neuralgia (PHN) and other HZ complications within 90 days of HZ onset were also estimated among patients with HZ. Risk factors for PHN in IC individuals with HZ were assessed by a multivariate regression model. RESULTS: The overall IR of HZ in the IC cohort was 7.8/1000 PY (95% CI 7.7 to 7.9), increasing with age from 3.5/1000 PY (3.4–3.7) in individuals aged 18–49 years to 12.6/1000 PY (12.2–13.0) in individuals aged ≥80 years. This IR in the IC-free cohort was 6.2/1000 PY (6.1–6.3). The overall IR of HZ varied across IC conditions, ranging from 5.3 (5.1–5.5) in psoriasis to 41.7/1000 PY (35.7–48.4) in HSCT. The proportions of PHN and other HZ complications were 10.7% (10.2–11.1) and 2.9% (2.7–3.2) in the IC cohort, but 9.1% (8.7–9.5) and 2.3% (2.1–2.6) in the IC-free cohort, respectively. CONCLUSION: IC population contributes to the public health burden of HZ in England. Vaccination might be the most preferable HZ preventive measure for the IC population. |
format | Online Article Text |
id | pubmed-6009512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-60095122018-06-25 Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 Yanni, Emad A. Ferreira, Germano Guennec, Morgane El Hahi, Yassine El Ghachi, Amale Haguinet, François Espie, Emmanuelle Bianco, Veronique BMJ Open Public Health OBJECTIVES: Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus which remains latent in individuals after a varicella infection. It is expected that HZ will be more frequent in immunocompromised (IC) individuals than in immunocompetent (IC-free). This study assessed the incidence rate (IR) of HZ in individuals with a wide set of IC conditions and in IC-free individuals. SETTING: A retrospective cohort study was conducted in England using data (January 2000 to March 2012) from the Clinical Practice Research Datalink with linkage to the Hospital Episodes Statistics. PARTICIPANTS: A cohort of 621 588 individuals with 16 selected IC conditions and a gender/age-matched cohort of IC-free individuals were identified. The IC conditions included haematopoietic stem cell transplant (HSCT), solid organ transplant, malignancies, autoimmune diseases and users of immunosuppressive medications. OUTCOMES: IR of HZ per 1000 person-years (PY) was estimated. Proportions of postherpetic neuralgia (PHN) and other HZ complications within 90 days of HZ onset were also estimated among patients with HZ. Risk factors for PHN in IC individuals with HZ were assessed by a multivariate regression model. RESULTS: The overall IR of HZ in the IC cohort was 7.8/1000 PY (95% CI 7.7 to 7.9), increasing with age from 3.5/1000 PY (3.4–3.7) in individuals aged 18–49 years to 12.6/1000 PY (12.2–13.0) in individuals aged ≥80 years. This IR in the IC-free cohort was 6.2/1000 PY (6.1–6.3). The overall IR of HZ varied across IC conditions, ranging from 5.3 (5.1–5.5) in psoriasis to 41.7/1000 PY (35.7–48.4) in HSCT. The proportions of PHN and other HZ complications were 10.7% (10.2–11.1) and 2.9% (2.7–3.2) in the IC cohort, but 9.1% (8.7–9.5) and 2.3% (2.1–2.6) in the IC-free cohort, respectively. CONCLUSION: IC population contributes to the public health burden of HZ in England. Vaccination might be the most preferable HZ preventive measure for the IC population. BMJ Publishing Group 2018-06-07 /pmc/articles/PMC6009512/ /pubmed/29880565 http://dx.doi.org/10.1136/bmjopen-2017-020528 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Public Health Yanni, Emad A. Ferreira, Germano Guennec, Morgane El Hahi, Yassine El Ghachi, Amale Haguinet, François Espie, Emmanuelle Bianco, Veronique Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 |
title | Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 |
title_full | Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 |
title_fullStr | Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 |
title_full_unstemmed | Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 |
title_short | Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 |
title_sort | burden of herpes zoster in 16 selected immunocompromised populations in england: a cohort study in the clinical practice research datalink 2000–2012 |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009512/ https://www.ncbi.nlm.nih.gov/pubmed/29880565 http://dx.doi.org/10.1136/bmjopen-2017-020528 |
work_keys_str_mv | AT yanniemada burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT ferreiragermano burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT guennecmorgane burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT elhahiyassine burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT elghachiamale burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT haguinetfrancois burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT espieemmanuelle burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 AT biancoveronique burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012 |